NexOptic Technology Corp. Signs MOU with IntroMedic, A Global Capsule Endoscopic Imaging Corporation

(“NexOptic“)and (“IntroMedic”) jointly announce that they have entered a non-binding memorandum of understanding (“MOU”). IntroMedic is a leading innovator in global capsule endoscopy technology and medical imaging analysis whose objective is to always improve the quality of its patented imaging and analysis medical offerings. Further detail can be found on IntroMedic’s website: IntroMedic.

“In our ongoing efforts to always put patients and medical experts first, I am very encouraged by the measurable improvements to image quality that NexOptic has been able to demonstrate to us.” Said Mr. Andrew Shim, President of IntroMedic.

Recommended AI: AI in Retail: Israeli Startup Hexa is Enabling Shoppers to View Products in 360 Degrees & Try Them Virtually

Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of the digestive tract. IntroMedic’s capsule endoscopy camera sits inside a vitamin-size capsule that is swallowed. As the capsule travels through the digestive tract, the camera takes thousands of pictures that are transmitted to a recorder worn on a belt around the patients’ waist. Growing in popularity, capsule endoscopy is far less invasive and more comfortable to the patient than more traditional endoscopy procedures.

Specifically, IntroMedic’s MiroCam capsule endoscope offers a broader field of view of 170 degrees which enables a more thorough diagnosis of parts of the digestive system, further its 12-hour operational time mitigates many concerns common in competitive offerings. Together with IntroMedic’s patented Human Body Communication technology (HBC), its Augmented Live-body Image Colour-Spectrum Enhancement (ALICE) and its Medical Image Processing technology (MIP), MiroCam delivers many technological advantages when compared to its competitors.

Recommended AI: Google Cloud Announces Biggest-ever Upgrade to Vertex AI

NexOptic and IntroMedic initiated dialogue late in 2021 and have undergone several stages of evaluation and development since.

Paul McKenzie, CEO of NexOptic stated, “It’s been an encouraging relationship with IntroMedic and we are excited for the possibility of playing a role in more technologies that further benefit human health and lifestyle.”

Today’s announcement demonstrates both companies’ positive outlook on executing a potential per capsule, licence model. If successful, this would mark the second commercial deployment of ALIIS into medical imaging devices, a field that NexOptic is well-positioned to rapidly expand into due to demanding use-cases that are frequently dependant on small lens factors.

Recommended AI: Is Customer Experience Strategy Making or Breaking Your ‘Shopping Festival’ Sales?

[To share your insights with us, please write to sghosh@martechseries.com]